Back to search
FDAFDA · Food and drugs·Recall number D-0339-2019

Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle, Rx Only,Distributed by Pfizer Inc. New York, NY 10017, NDC 60793-855-01

Published December 26, 2018 · Recall initiated: December 6, 2018

Summary

FDA records drug Class II recall D-0339-2019, published December 26, 2018 and initiated December 6, 2018. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 1996 bottles; Lot: Lot #:18A18, Exp. 01/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent Drug.

What to do

Voluntary: Firm initiated · Letter

Get an email if LEVOXYL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LEVOXYL
Manufacturer
Pfizer Inc.
Distributor
Nationwide within the United States
UPC
0360793856018
Lot
Lot #:18A18, Exp. 01/2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle, Rx Only,Distributed by Pfizer Inc. New York, NY 10017, NDC 60793-855-01 recalled?

Yes. FDA published recall D-0339-2019 on December 26, 2018. Reported hazard: Superpotent Drug.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LEVOXYL. UPC: 0360793856018.